Identification

Name
Dosulepin
Accession Number
DB09167
Type
Small Molecule
Groups
Approved
Description

Dosulepin (INN, BAN) formerly known as dothiepin (USAN), is a tricyclic antidepressant with anxiolytic properties that is used in several European and South Asian countries, as well as Australia, South Africa, and New Zealand. It is not FDA-approved due to low therpeutic index and significant toxicity in overdose. Dosulepin inhibits the reuptake of biogenic amines, increasing available neurotransmitter levels at the synaptic cleft. The use of dosulepsin is only recommended in patients who are intolerant or unresponsive to alternative antidepressant therapies. Dosulepsin is a thio derivative of Amitriptyline with a similar efficacy to that of Amitriptyline, and also exhibits anticholinergic, antihistamine and central sedative properties [8]. Its hydrochloride form is a common active ingredient in different drug formulations.

Structure
Thumb
Synonyms
  • (3E)-3-dibenzo[b,e]thiepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine
  • 11-(3-Dimethylaminopropylidene)-6,11-dihydrodibenzo(b,e)thiepin
  • Dosulepina
  • Dosulépine
  • Dosulepinum
  • Dothiepin
  • trans-dothiepin
Product Ingredients
IngredientUNIICASInChI Key
Dosulepin hydrochloride3H0042311V897-15-4XUPZAARQDNSRJB-SJDTYFKWSA-N
International/Other Brands
Depropin (CCM Duopharma Biotech) / Dopress (Mylan) / Dothip (Micro Synapse) / Dothitab (Psycorem) / Dotopine (Shou Chan) / Elate (Crescent) / Espin (Taejoon Pharm) / Harmomed (Kwizda) / Othtric (Cubit) / Prothiaden (Abbott) / Prothiaden (Teofarma) / Qualiaden (Quality Pharm) / Singsong (Yuan Chou) / Thaden (Pharmacare) / Vick-Thiaden (Vickmans)
Categories
UNII
W13O82Z7HL
CAS number
113-53-1
Weight
Average: 295.44
Monoisotopic: 295.139470854
Chemical Formula
C19H21NS
InChI Key
PHTUQLWOUWZIMZ-GZTJUZNOSA-N
InChI
InChI=1S/C19H21NS/c1-20(2)13-7-11-17-16-9-4-3-8-15(16)14-21-19-12-6-5-10-18(17)19/h3-6,8-12H,7,13-14H2,1-2H3/b17-11+
IUPAC Name
dimethyl({3-[(2E)-9-thiatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,11,13-hexaen-2-ylidene]propyl})amine
SMILES
CN(C)CC\C=C1/C2=CC=CC=C2CSC2=CC=CC=C12

Pharmacology

Indication

Indicated in the treatment of symptoms of depressive illness, especially where an anti-anxiety effect is required.

Structured Indications
Not Available
Pharmacodynamics

Dosulepin is a tricyclic antidepressant that interacts with various receptors and transporters. It is a monoamine reuptake inhibitor with approximately equal potency for noradrenaline and 5-HT that increases the availability of these neurotransmitters at the central synapses [8]. The metabolites of dosulepin are shown to inhibit 5HT uptake by the human blood platelet [2].

Mechanism of action

By binding to noradrenaline transporter (NAT) and serotonin transporter (SERT) in an equipotent manner and inhibiting the reuptake activity, dosulepin increases the free levels of noradrenaline and 5HT at the synaptic cleft. It is shown that the main metabolite northiaden is a more potent inhibitor of noradrenaline uptake than the parent drug [5].

Dosulepin displays affinity towards α2-adrenoceptors and to a lesser extent, α1-adrenoceptors [4]. Inhibition of presynaptic α2-adrenoceptors by dosulepin facilitates noradrenaline release and further potentiates the antidepressant effects [5]. It also downregulates central β-adrenoceptors by causing a decline in the number of receptors and reduces noradrenaline-induced cyclic AMP formation [7, 5]. Dosulepin binds to 5HT1A and 5HT2A receptors in the cerebral cortex and hippocampus as an antagonist. 5HT1A receptors are autoreceptors that inhibit 5HT release and 5HT2A receptors are Gi/Go-coupled receptors that reduces dopamine release upon activation [6]. Antagonism at 5HT2A receptors may also improve sleep patterns. Dosulepin also binds to muscarinic acetylcholine receptors and causes antimuscarinic side effects such as dry mouth. By acting as an antagonist at histamine type 1 (H1) receptors, dosulepin mediates a sedative effect.

Main metabolites northiaden, dothiepin sulphoxide and northiaden sulphoxide may also bind to 5HT, α2 and H1 receptors, although with less affinity compared to the parent drug [3].

TargetActionsOrganism
A5-hydroxytryptamine receptor 1A
antagonist
Human
A5-hydroxytryptamine receptor 2A
antagonist
Human
AHistamine H1 receptor
antagonist
Human
AMuscarinic acetylcholine receptor M1
antagonist
Human
AMuscarinic acetylcholine receptor M2
antagonist
Human
AMuscarinic acetylcholine receptor M3
antagonist
Human
AMuscarinic acetylcholine receptor M4
antagonist
Human
AMuscarinic acetylcholine receptor M5
antagonist
Human
AAlpha-2 adrenergic receptors
antagonist
Human
AAlpha-1 adrenergic receptors
antagonist
Human
ASodium-dependent noradrenaline transporter
inhibitor
Human
ASodium-dependent serotonin transporter
inhibitor
Human
Absorption

Dosulepin is well absorbed from the intestines to reach the peak plasma concentration of 37.6ng/mL at 2.18 hours (Tmax) following oral administration of 25mg [7]. The steady state concentrations are variable among individuals due to dynamic relationship between the drug dose and plasma concentration [8].

Volume of distribution

The mean apparent Vd is approximately 45 L/kg after oral administration of 75mg dosulepin [2]. It crosses the blood-brain barrier to mediate its antidepressant actions and also crosses the placental barriers, with low concentration of the drug excreted in breast milk [8].

Protein binding

Approximately 84% of unchanged drug is bound to serum protein [8].

Metabolism

Dosulepin undergoes extensive hepatic metabolism, to form main metabolites N-demethylated derivative northiaden (desmethyldosulepin or northiaden) and dosulepin S-oxide. Northiaden S-oxide is among 12 basic metabolites that are found in urine. The metabolic pathways of dosulepin is thought to involve N-demethylation, S-oxidation and glucuronic acid conjugation [8].

Route of elimination

Dosulepin is predominantly cleared via renal elimination, mainly in the form of metabolites. Renal excretion of dosulepin and its metabolites accounts for 50% - 60% of total elimination, and biliary/fecal excretion is about 15%-40% [7].

Half life

The elimination half life is approximately 20.4 hours following oral administration of 25mg dosulepin [7].

Clearance

Oral clearance is approximately 1.36 L/kg * hr following a single oral dose of 75mg dosulepin [2].

Toxicity

High mortality is associated with overdose of dosulepin (>5mg/kg) with the onset of toxicity occuring within 4-6 hours. Dosulepin may increase the risk of cardiovascular toxicity (cardiac arrhythmias, conduction disorders, cardiac failure and circulatory collapse) and severe hypotension, especially in the elderly [7]. Withdrawal symptoms are reported in case of sudden cessation of therapy, which include insomnia, irritability, headache, nausea, giddiness, panic-anxiety, extreme motor restlessness and excessive perspiration. There have been reports of increased suicidal thoughts or behaviour with dosulepin treatment. Oral lowest published toxic dose (Toxic Dose Low, TDLo) is 90 mg/kg in infants and 4.5 mg/kg in female adults. Intravenous LD50 in mouse is 31 mg/kg [MSDS].

Most common adverse effects involve the central nervous system (drowsiness, extrapyramidal symptoms, tremor, confusional states, disorientation, dizziness, paraesthesia, alterations to EEG patterns), anticholinergic effects (dry mouth, sweating, urinary retention), cardiovascular system (hypotension, postural hypotension, tachycardia, palpitations, arrhythmias, conduction defects), endocrine system (altered libido), gastrointestinal system (nausea, vomiting, constipation) and blurred vision [8].

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe serum concentration of Dosulepin can be increased when it is combined with 1,10-Phenanthroline.Experimental
2,5-Dimethoxy-4-ethylamphetamineDosulepin may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-DichloroisocoumarinThe serum concentration of Dosulepin can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
3,4-MethylenedioxyamphetamineDosulepin may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-(2-Aminoethyl)Benzenesulfonyl FluorideThe serum concentration of Dosulepin can be increased when it is combined with 4-(2-Aminoethyl)Benzenesulfonyl Fluoride.Experimental
4-Bromo-2,5-dimethoxyamphetamineDosulepin may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineDosulepin may decrease the antihypertensive activities of 4-Methoxyamphetamine.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Dosulepin.Experimental
AceclofenacThe metabolism of Aceclofenac can be decreased when combined with Dosulepin.Approved, Investigational
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Dosulepin.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Dosulepin.Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Dosulepin.Approved
Acetylsalicylic acidThe metabolism of Acetylsalicylic acid can be decreased when combined with Dosulepin.Approved, Vet Approved
AgmatineDosulepin may decrease the antihypertensive activities of Agmatine.Experimental, Investigational
AgomelatineThe serum concentration of Agomelatine can be increased when it is combined with Dosulepin.Approved, Investigational
AjmalineThe metabolism of Ajmaline can be decreased when combined with Dosulepin.Approved, Investigational
AlaproclateThe serum concentration of Dosulepin can be increased when it is combined with Alaproclate.Experimental
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Dosulepin.Approved, Vet Approved
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Dosulepin.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Dosulepin.Approved
AlosetronThe metabolism of Alosetron can be decreased when combined with Dosulepin.Approved, Withdrawn
Alpha-1-proteinase inhibitorThe serum concentration of Dosulepin can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Dosulepin.Approved, Illicit, Investigational
AlprenololThe metabolism of Alprenolol can be decreased when combined with Dosulepin.Approved, Withdrawn
AltretamineAltretamine may increase the orthostatic hypotensive activities of Dosulepin.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Dosulepin.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Dosulepin.Approved
AmiodaroneThe metabolism of Amiodarone can be decreased when combined with Dosulepin.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Dosulepin.Approved
AmobarbitalThe metabolism of Dosulepin can be increased when combined with Amobarbital.Approved, Illicit
AmoxapineThe metabolism of Amoxapine can be decreased when combined with Dosulepin.Approved
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Dosulepin.Approved, Illicit
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Dosulepin.Approved
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Dosulepin.Approved
AnagrelideThe metabolism of Anagrelide can be decreased when combined with Dosulepin.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Dosulepin.Approved
Antithrombin III humanThe serum concentration of Dosulepin can be increased when it is combined with Antithrombin III human.Approved
ApixabanThe metabolism of Apixaban can be decreased when combined with Dosulepin.Approved
ApomorphineDosulepin may decrease the antihypertensive activities of Apomorphine.Approved, Investigational
ApraclonidineDosulepin may decrease the antihypertensive activities of Apraclonidine.Approved
AprepitantThe metabolism of Aprepitant can be decreased when combined with Dosulepin.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Dosulepin.Approved
AprotininThe serum concentration of Dosulepin can be increased when it is combined with Aprotinin.Approved, Withdrawn
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Dosulepin.Experimental
ArbutamineThe risk or severity of adverse effects can be increased when Dosulepin is combined with Arbutamine.Approved
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Dosulepin.Approved, Investigational
ArgatrobanThe serum concentration of Dosulepin can be increased when it is combined with Argatroban.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Dosulepin.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Dosulepin.Approved
AsenapineThe metabolism of Asenapine can be decreased when combined with Dosulepin.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Dosulepin.Approved, Withdrawn
AsunaprevirThe serum concentration of Dosulepin can be increased when it is combined with Asunaprevir.Approved, Investigational
AtazanavirThe metabolism of Atazanavir can be decreased when combined with Dosulepin.Approved, Investigational
AtomoxetineThe serum concentration of Atomoxetine can be increased when it is combined with Dosulepin.Approved
AxitinibThe metabolism of Axitinib can be decreased when combined with Dosulepin.Approved, Investigational
AzelastineThe metabolism of Azelastine can be decreased when combined with Dosulepin.Approved
BambuterolThe risk or severity of adverse effects can be increased when Dosulepin is combined with Bambuterol.Approved, Investigational
BarbexacloneThe metabolism of Dosulepin can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Dosulepin can be increased when combined with Barbital.Illicit
BatimastatThe serum concentration of Dosulepin can be increased when it is combined with Batimastat.Experimental
BenazeprilThe serum concentration of Dosulepin can be increased when it is combined with Benazepril.Approved, Investigational
BendamustineThe serum concentration of Bendamustine can be increased when it is combined with Dosulepin.Approved, Investigational
BenmoxinBenmoxin may increase the serotonergic activities of Dosulepin.Withdrawn
BenzamidineThe serum concentration of Dosulepin can be increased when it is combined with Benzamidine.Experimental
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Dosulepin.Approved
BenzphetamineDosulepin may decrease the antihypertensive activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Dosulepin.Approved
BepridilThe metabolism of Bepridil can be decreased when combined with Dosulepin.Approved, Withdrawn
BetaxololThe metabolism of Betaxolol can be decreased when combined with Dosulepin.Approved
BethanidineDosulepin may decrease the antihypertensive activities of Bethanidine.Approved
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Dosulepin.Approved, Investigational
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Dosulepin.Approved
BivalirudinThe serum concentration of Dosulepin can be increased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Dosulepin can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Bortezomib can be decreased when combined with Dosulepin.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Dosulepin.Approved, Investigational
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Dosulepin.Approved
BrimonidineDosulepin may decrease the antihypertensive activities of Brimonidine.Approved
BrivaracetamThe metabolism of Brivaracetam can be decreased when combined with Dosulepin.Approved, Investigational
BrofaromineBrofaromine may increase the serotonergic activities of Dosulepin.Experimental
BromazepamThe metabolism of Bromazepam can be decreased when combined with Dosulepin.Approved, Illicit
BromocriptineDosulepin may decrease the antihypertensive activities of Bromocriptine.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Dosulepin.Approved
BufuralolThe metabolism of Bufuralol can be decreased when combined with Dosulepin.Experimental, Investigational
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Dosulepin.Approved, Investigational
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Dosulepin.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Dosulepin can be decreased when combined with Bupropion.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Dosulepin.Approved, Investigational
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Dosulepin.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Dosulepin.Approved
CamostatThe serum concentration of Dosulepin can be increased when it is combined with Camostat.Experimental
CandesartanThe metabolism of Candesartan can be decreased when combined with Dosulepin.Experimental
Candesartan cilexetilThe metabolism of Candesartan cilexetil can be decreased when combined with Dosulepin.Approved
CandoxatrilThe serum concentration of Dosulepin can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Dosulepin can be increased when it is combined with Candoxatrilat.Experimental
CaptoprilThe metabolism of Captopril can be decreased when combined with Dosulepin.Approved
CarbamazepineThe metabolism of Dosulepin can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Dosulepin.Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Dosulepin.Approved
CarmustineThe metabolism of Carmustine can be decreased when combined with Dosulepin.Approved
CaroxazoneCaroxazone may increase the serotonergic activities of Dosulepin.Withdrawn
CarteololThe metabolism of Carteolol can be decreased when combined with Dosulepin.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Dosulepin.Approved, Investigational
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Dosulepin.Approved, Investigational
CeliprololThe risk or severity of adverse effects can be increased when Dosulepin is combined with Celiprolol.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Dosulepin.Approved, Vet Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Dosulepin.Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Dosulepin.Approved, Illicit
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Dosulepin.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Dosulepin.Approved
ChlorphentermineDosulepin may increase the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Dosulepin.Approved, Vet Approved
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Dosulepin.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Dosulepin.Approved
CholesterolThe serum concentration of Dosulepin can be increased when it is combined with Cholesterol.Experimental, Investigational
ChymostatinThe serum concentration of Dosulepin can be increased when it is combined with Chymostatin.Experimental
CilastatinThe serum concentration of Dosulepin can be increased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Dosulepin can be increased when it is combined with Cilazapril.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Dosulepin.Approved
CimetidineThe metabolism of Dosulepin can be decreased when combined with Cimetidine.Approved
CinacalcetThe serum concentration of Dosulepin can be increased when it is combined with Cinacalcet.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Dosulepin.Approved, Investigational
CirazolineDosulepin may increase the vasopressor activities of Cirazoline.Experimental
CisaprideThe metabolism of Cisapride can be decreased when combined with Dosulepin.Approved, Investigational, Withdrawn
CitalopramThe risk or severity of adverse effects can be increased when Dosulepin is combined with Citalopram.Approved
ClenbuterolThe metabolism of Clenbuterol can be decreased when combined with Dosulepin.Approved, Investigational, Vet Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Dosulepin.Approved
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Dosulepin.Approved, Vet Approved
ClonidineDosulepin may decrease the antihypertensive activities of Clonidine.Approved
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Dosulepin.Approved, Nutraceutical
ClorindioneDosulepin may increase the anticoagulant activities of Clorindione.Experimental
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Dosulepin.Approved
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Dosulepin.Approved, Illicit
Conjugated estrogensThe metabolism of Conjugated estrogens can be decreased when combined with Dosulepin.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Dosulepin.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Dosulepin.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dosulepin can be increased when it is combined with Dabigatran etexilate.Approved
DacarbazineThe metabolism of Dacarbazine can be decreased when combined with Dosulepin.Approved, Investigational
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Dosulepin.Approved
DapoxetineThe serum concentration of Dosulepin can be increased when it is combined with Dapoxetine.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Dosulepin.Approved, Investigational
DarexabanThe serum concentration of Dosulepin can be increased when it is combined with Darexaban.Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Dosulepin.Approved, Investigational
DarunavirThe serum concentration of Dosulepin can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Dosulepin.Approved
DasatinibThe metabolism of Dasatinib can be decreased when combined with Dosulepin.Approved, Investigational
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Dosulepin.Approved
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Dosulepin.Approved, Investigational
DelanzomibThe serum concentration of Dosulepin can be increased when it is combined with Delanzomib.Investigational
DelaprilThe serum concentration of Dosulepin can be increased when it is combined with Delapril.Experimental
DelavirdineThe metabolism of Delavirdine can be decreased when combined with Dosulepin.Approved
DesipramineThe metabolism of Desipramine can be decreased when combined with Dosulepin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Dosulepin is combined with Desmopressin.Approved
DesvenlafaxineThe serum concentration of Dosulepin can be increased when it is combined with Desvenlafaxine.Approved
DeutetrabenazineThe metabolism of Deutetrabenazine can be decreased when combined with Dosulepin.Approved, Investigational
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be decreased when combined with Dosulepin.Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Dosulepin.Approved, Illicit, Investigational, Withdrawn
DexmedetomidineDosulepin may decrease the antihypertensive activities of Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Dosulepin.Approved
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Dosulepin.Approved, Illicit
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Dosulepin.Approved
DiazepamThe metabolism of Diazepam can be decreased when combined with Dosulepin.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Diclofenac can be increased when it is combined with Dosulepin.Approved, Vet Approved
DicoumarolThe metabolism of Dicoumarol can be decreased when combined with Dosulepin.Approved
DiethylpropionDosulepin may increase the stimulatory activities of Diethylpropion.Approved, Illicit
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Dosulepin.Approved, Illicit
DihydroergotamineDosulepin may decrease the antihypertensive activities of Dihydroergotamine.Approved
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Dosulepin.Approved
DinoprostoneThe metabolism of Dinoprostone can be decreased when combined with Dosulepin.Approved
DiphenadioneDosulepin may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Dosulepin.Approved
DipivefrinDosulepin may decrease the antihypertensive activities of Dipivefrin.Approved
DobutamineThe risk or severity of adverse effects can be increased when Dosulepin is combined with Dobutamine.Approved
DoconexentThe metabolism of Doconexent can be decreased when combined with Dosulepin.Approved, Investigational
DolasetronThe metabolism of Dolasetron can be decreased when combined with Dosulepin.Approved
DomperidoneThe metabolism of Domperidone can be decreased when combined with Dosulepin.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Dosulepin.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Dosulepin.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Dosulepin.Approved
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Dosulepin.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Dosulepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Dosulepin.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Dosulepin.Approved, Investigational
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Dosulepin.Approved, Illicit
DronedaroneThe metabolism of Dronedarone can be decreased when combined with Dosulepin.Approved
DroxidopaDosulepin may decrease the antihypertensive activities of Droxidopa.Approved, Investigational
DuloxetineDuloxetine may increase the serotonergic activities of Dosulepin.Approved
EcabetThe serum concentration of Dosulepin can be increased when it is combined with Ecabet.Approved, Investigational
EdoxabanThe serum concentration of Dosulepin can be increased when it is combined with Edoxaban.Approved
ElafinThe serum concentration of Dosulepin can be increased when it is combined with Elafin.Investigational
EletriptanThe metabolism of Eletriptan can be decreased when combined with Dosulepin.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Dosulepin.Approved
EltrombopagThe metabolism of Eltrombopag can be decreased when combined with Dosulepin.Approved
EnalaprilThe serum concentration of Dosulepin can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Dosulepin can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Dosulepin can be increased when it is combined with Enalkiren.Experimental
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Dosulepin.Approved
EncainideThe metabolism of Encainide can be decreased when combined with Dosulepin.Approved, Investigational, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Dosulepin.Investigational
EphedraDosulepin may decrease the antihypertensive activities of Ephedra.Approved, Nutraceutical, Withdrawn
Epigallocatechin GallateThe serum concentration of Dosulepin can be increased when it is combined with Epigallocatechin Gallate.Investigational
EpinastineThe metabolism of Epinastine can be decreased when combined with Dosulepin.Approved, Investigational
EpinephrineDosulepin may decrease the antihypertensive activities of Epinephrine.Approved, Vet Approved
EpoprostenolThe metabolism of Epoprostenol can be decreased when combined with Dosulepin.Approved
ErgotamineDosulepin may decrease the antihypertensive activities of Ergotamine.Approved
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Dosulepin.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Dosulepin is combined with Escitalopram.Approved, Investigational
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Dosulepin.Investigational
EstradiolThe metabolism of Estradiol can be decreased when combined with Dosulepin.Approved, Investigational, Vet Approved
EstroneThe metabolism of Estrone can be decreased when combined with Dosulepin.Approved
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Dosulepin.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Dosulepin.Approved
EthanolThe metabolism of Ethanol can be decreased when combined with Dosulepin.Approved
Ethyl biscoumacetateDosulepin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Dosulepin.Approved, Illicit
EtodolacThe metabolism of Etodolac can be decreased when combined with Dosulepin.Approved, Investigational, Vet Approved
EtomidateDosulepin may decrease the antihypertensive activities of Etomidate.Approved
EtoperidoneThe serum concentration of Dosulepin can be increased when it is combined with Etoperidone.Withdrawn
EtoposideThe metabolism of Etoposide can be decreased when combined with Dosulepin.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Dosulepin.Approved, Investigational
EtravirineThe metabolism of Etravirine can be decreased when combined with Dosulepin.Approved
FaldaprevirThe serum concentration of Dosulepin can be increased when it is combined with Faldaprevir.Investigational
FenoterolThe risk or severity of adverse effects can be increased when Dosulepin is combined with Fenoterol.Approved, Investigational
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dosulepin.Approved
FingolimodThe metabolism of Fingolimod can be decreased when combined with Dosulepin.Approved, Investigational
FlecainideThe metabolism of Flecainide can be decreased when combined with Dosulepin.Approved, Withdrawn
FluindioneDosulepin may increase the anticoagulant activities of Fluindione.Investigational
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Dosulepin.Approved
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Dosulepin.Approved, Illicit
FluorouracilThe metabolism of Fluorouracil can be decreased when combined with Dosulepin.Approved
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Dosulepin.Approved, Vet Approved
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Dosulepin.Approved
FlurbiprofenThe metabolism of Flurbiprofen can be decreased when combined with Dosulepin.Approved, Investigational
FlutamideThe metabolism of Flutamide can be decreased when combined with Dosulepin.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Dosulepin.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Dosulepin.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Dosulepin.Approved, Investigational
FosamprenavirThe serum concentration of Dosulepin can be increased when it is combined with Fosamprenavir.Approved
FosinoprilThe serum concentration of Dosulepin can be increased when it is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Fosphenytoin can be decreased when combined with Dosulepin.Approved
FrovatriptanThe metabolism of Frovatriptan can be decreased when combined with Dosulepin.Approved, Investigational
FurazolidoneFurazolidone may increase the serotonergic activities of Dosulepin.Approved, Investigational, Vet Approved
GabexateThe serum concentration of Dosulepin can be increased when it is combined with Gabexate.Investigational
GalantamineThe metabolism of Galantamine can be decreased when combined with Dosulepin.Approved
GavestinelThe metabolism of Gavestinel can be decreased when combined with Dosulepin.Investigational
GefitinibThe metabolism of Gefitinib can be decreased when combined with Dosulepin.Approved, Investigational
GeldanamycinThe serum concentration of Dosulepin can be increased when it is combined with Geldanamycin.Experimental, Investigational
GenisteinThe metabolism of Genistein can be decreased when combined with Dosulepin.Investigational
GepefrineDosulepin may increase the stimulatory activities of Gepefrine.Experimental
GliclazideThe metabolism of Gliclazide can be decreased when combined with Dosulepin.Approved
GlimepirideThe metabolism of Glimepiride can be decreased when combined with Dosulepin.Approved
GlipizideThe metabolism of Glipizide can be decreased when combined with Dosulepin.Approved
GlyburideThe metabolism of Glyburide can be decreased when combined with Dosulepin.Approved
GM6001The serum concentration of Dosulepin can be increased when it is combined with GM6001.Experimental
GranisetronThe metabolism of Granisetron can be decreased when combined with Dosulepin.Approved, Investigational
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Dosulepin.Investigational, Withdrawn
GuanabenzDosulepin may decrease the antihypertensive activities of Guanabenz.Approved, Investigational
GuanfacineDosulepin may decrease the antihypertensive activities of Guanfacine.Approved, Investigational
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Dosulepin.Approved
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Dosulepin.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Dosulepin.Approved, Vet Approved
HarmalineHarmaline may increase the serotonergic activities of Dosulepin.Experimental
HesperetinThe metabolism of Hesperetin can be decreased when combined with Dosulepin.Approved
HexobarbitalThe metabolism of Dosulepin can be increased when combined with Hexobarbital.Approved
HistamineThe metabolism of Histamine can be decreased when combined with Dosulepin.Approved, Investigational
HydracarbazineHydracarbazine may increase the serotonergic activities of Dosulepin.Experimental
HydrocodoneThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Dosulepin resulting in a loss in efficacy.Approved, Illicit
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Dosulepin.Approved, Illicit
HydroxyamphetamineDosulepin may increase the stimulatory activities of Hydroxyamphetamine.Approved
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Dosulepin.Approved
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Dosulepin.Approved
IcotinibThe metabolism of Icotinib can be decreased when combined with Dosulepin.Approved, Investigational
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Dosulepin.Approved
IdraparinuxThe serum concentration of Dosulepin can be increased when it is combined with Idraparinux.Investigational
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Dosulepin.Approved
IloperidoneThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Dosulepin.Approved
ImatinibThe metabolism of Imatinib can be decreased when combined with Dosulepin.Approved
ImidaprilThe serum concentration of Dosulepin can be increased when it is combined with Imidapril.Investigational
ImipramineThe metabolism of Imipramine can be decreased when combined with Dosulepin.Approved
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Dosulepin.Approved, Investigational
IndacaterolThe risk or severity of adverse effects can be increased when Dosulepin is combined with Indacaterol.Approved
IndalpineThe serum concentration of Dosulepin can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndinavirThe serum concentration of Dosulepin can be increased when it is combined with Indinavir.Approved
indisulamThe metabolism of indisulam can be decreased when combined with Dosulepin.Investigational
IndomethacinThe metabolism of Indomethacin can be decreased when combined with Dosulepin.Approved, Investigational
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Dosulepin.Approved, Investigational
Iofetamine I-123Dosulepin may increase the stimulatory activities of Iofetamine I-123.Approved
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Dosulepin.Approved
IproclozideIproclozide may increase the serotonergic activities of Dosulepin.Withdrawn
IproniazidIproniazid may increase the serotonergic activities of Dosulepin.Withdrawn
IrbesartanThe metabolism of Irbesartan can be decreased when combined with Dosulepin.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Dosulepin.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Dosulepin is combined with Isoetarine.Approved
IsoflurophateThe serum concentration of Dosulepin can be increased when it is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsoprenalineThe risk or severity of adverse effects can be increased when Dosulepin is combined with Isoprenaline.Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Dosulepin.Approved
KetamineThe metabolism of Ketamine can be decreased when combined with Dosulepin.Approved, Vet Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Dosulepin.Approved, Investigational
KetoprofenThe metabolism of Ketoprofen can be decreased when combined with Dosulepin.Approved, Vet Approved
LabetalolThe metabolism of Labetalol can be decreased when combined with Dosulepin.Approved
LacosamideThe serum concentration of Lacosamide can be increased when it is combined with Dosulepin.Approved
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Dosulepin.Approved, Investigational
LeflunomideThe metabolism of Leflunomide can be decreased when combined with Dosulepin.Approved, Investigational
LepirudinThe serum concentration of Dosulepin can be increased when it is combined with Lepirudin.Approved
LesinuradThe metabolism of Lesinurad can be decreased when combined with Dosulepin.Approved
LetaxabanThe serum concentration of Dosulepin can be increased when it is combined with Letaxaban.Investigational
LetermovirThe metabolism of Letermovir can be decreased when combined with Dosulepin.Approved
LevobupivacaineThe metabolism of Levobupivacaine can be decreased when combined with Dosulepin.Approved, Investigational
LevodopaThe metabolism of Levodopa can be decreased when combined with Dosulepin.Approved
LevomilnacipranThe serum concentration of Dosulepin can be increased when it is combined with Levomilnacipran.Approved
LevonordefrinDosulepin may decrease the antihypertensive activities of Levonordefrin.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when Dosulepin is combined with Levosalbutamol.Approved
LevothyroxineLevothyroxine may increase the arrhythmogenic activities of Dosulepin.Approved
LicofeloneThe metabolism of Licofelone can be decreased when combined with Dosulepin.Investigational
LidocaineThe metabolism of Lidocaine can be decreased when combined with Dosulepin.Approved, Vet Approved
LinagliptinThe serum concentration of Dosulepin can be increased when it is combined with Linagliptin.Approved
LinezolidLinezolid may increase the serotonergic activities of Dosulepin.Approved, Investigational
LiothyronineLiothyronine may increase the arrhythmogenic activities of Dosulepin.Approved, Vet Approved
LiotrixLiotrix may increase the arrhythmogenic activities of Dosulepin.Approved
LisdexamfetamineDosulepin may increase the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LisinoprilThe serum concentration of Dosulepin can be increased when it is combined with Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Dosulepin.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Dosulepin.Approved
LofexidineDosulepin may decrease the antihypertensive activities of Lofexidine.Approved, Investigational
LomefloxacinThe metabolism of Lomefloxacin can be decreased when combined with Dosulepin.Approved, Investigational
LomustineThe metabolism of Lomustine can be decreased when combined with Dosulepin.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Dosulepin.Approved
LopinavirThe serum concentration of Dosulepin can be increased when it is combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Dosulepin.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Dosulepin.Approved
LornoxicamThe metabolism of Lornoxicam can be decreased when combined with Dosulepin.Approved, Investigational
LosartanThe metabolism of Losartan can be decreased when combined with Dosulepin.Approved
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Dosulepin.Approved, Investigational
MalathionThe metabolism of Malathion can be decreased when combined with Dosulepin.Approved, Investigational
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Dosulepin.Approved
MebanazineMebanazine may increase the serotonergic activities of Dosulepin.Withdrawn
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Dosulepin.Approved
MelagatranThe serum concentration of Dosulepin can be increased when it is combined with Melagatran.Experimental
MelatoninThe metabolism of Melatonin can be decreased when combined with Dosulepin.Approved, Nutraceutical, Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Dosulepin.Approved, Vet Approved
MenadioneThe metabolism of Menadione can be decreased when combined with Dosulepin.Approved, Nutraceutical
MephedroneDosulepin may increase the stimulatory activities of Mephedrone.Investigational
MephentermineDosulepin may increase the vasopressor activities of Mephentermine.Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Dosulepin.Investigational, Withdrawn
MequitazineThe serum concentration of Mequitazine can be increased when it is combined with Dosulepin.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Dosulepin.Approved, Investigational
MestranolThe metabolism of Mestranol can be decreased when combined with Dosulepin.Approved
MetaraminolDosulepin may increase the vasopressor activities of Metaraminol.Approved, Investigational
MethadoneThe metabolism of Methadone can be decreased when combined with Dosulepin.Approved
MethamphetamineDosulepin may decrease the antihypertensive activities of Methamphetamine.Approved, Illicit
MethohexitalThe metabolism of Dosulepin can be increased when combined with Methohexital.Approved
MethotrimeprazineThe metabolism of Methotrimeprazine can be decreased when combined with Dosulepin.Approved
MethoxamineDosulepin may increase the vasopressor activities of Methoxamine.Approved, Investigational
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Dosulepin.Approved, Investigational, Vet Approved
MethoxyphenamineDosulepin may increase the stimulatory activities of Methoxyphenamine.Experimental
Methylene blueDosulepin may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Dosulepin.Approved, Investigational
MethylphenobarbitalThe metabolism of Dosulepin can be increased when combined with Methylphenobarbital.Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Dosulepin.Approved, Illicit, Withdrawn
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Dosulepin.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Dosulepin.Approved, Investigational
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Dosulepin.Approved
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Dosulepin.Approved
MexiletineThe metabolism of Mexiletine can be decreased when combined with Dosulepin.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Dosulepin.Approved, Investigational
MidodrineDosulepin may increase the vasopressor activities of Midodrine.Approved
MidomafetamineDosulepin may increase the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MilnacipranThe serum concentration of Dosulepin can be increased when it is combined with Milnacipran.Approved
MinaprineThe metabolism of Minaprine can be decreased when combined with Dosulepin.Approved
MirabegronThe metabolism of Mirabegron can be decreased when combined with Dosulepin.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Dosulepin.Approved
MMDADosulepin may increase the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Dosulepin.Approved
MoexiprilThe serum concentration of Dosulepin can be increased when it is combined with Moexipril.Approved
MontelukastThe metabolism of Montelukast can be decreased when combined with Dosulepin.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Dosulepin.Approved, Investigational
MoxonidineThe therapeutic efficacy of Moxonidine can be decreased when used in combination with Dosulepin.Approved, Investigational
muraglitazarThe metabolism of muraglitazar can be decreased when combined with Dosulepin.Investigational
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Dosulepin can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NabumetoneThe metabolism of Nabumetone can be decreased when combined with Dosulepin.Approved
NafamostatThe serum concentration of Dosulepin can be increased when it is combined with Nafamostat.Approved, Investigational
NaphazolineDosulepin may decrease the antihypertensive activities of Naphazoline.Approved
NaproxenThe metabolism of Naproxen can be decreased when combined with Dosulepin.Approved, Vet Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Dosulepin.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Dosulepin.Approved, Investigational
NefazodoneThe serum concentration of Dosulepin can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Dosulepin can be increased when it is combined with Nelfinavir.Approved
NetupitantThe metabolism of Netupitant can be decreased when combined with Dosulepin.Approved
NevirapineThe metabolism of Nevirapine can be decreased when combined with Dosulepin.Approved
NialamideNialamide may increase the serotonergic activities of Dosulepin.Withdrawn
NicardipineThe metabolism of Nicardipine can be decreased when combined with Dosulepin.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Dosulepin.Approved, Investigational
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Dosulepin.Approved, Investigational, Vet Approved
NicorandilDosulepin may increase the hypotensive activities of Nicorandil.Approved, Investigational
NicotineThe metabolism of Nicotine can be decreased when combined with Dosulepin.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Dosulepin.Approved
Nitric OxideThe metabolism of Nitric Oxide can be decreased when combined with Dosulepin.Approved
NitroaspirinThe serum concentration of Dosulepin can be increased when it is combined with Nitroaspirin.Investigational
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Dosulepin.Approved, Investigational, Vet Approved
NorepinephrineDosulepin may decrease the antihypertensive activities of Norepinephrine.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Dosulepin.Approved
OctamoxinOctamoxin may increase the serotonergic activities of Dosulepin.Withdrawn
OlanzapineThe metabolism of Olanzapine can be decreased when combined with Dosulepin.Approved, Investigational
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Dosulepin.Approved
OmapatrilatThe serum concentration of Dosulepin can be increased when it is combined with Omapatrilat.Investigational
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Dosulepin.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Dosulepin.Approved
OrciprenalineThe risk or severity of adverse effects can be increased when Dosulepin is combined with Orciprenaline.Approved
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Dosulepin.Approved
OtamixabanThe serum concentration of Dosulepin can be increased when it is combined with Otamixaban.Investigational
OxaliplatinThe metabolism of Oxaliplatin can be decreased when combined with Dosulepin.Approved, Investigational
OxaprozinThe metabolism of Oxaprozin can be decreased when combined with Dosulepin.Approved
OxtriphyllineThe metabolism of Oxtriphylline can be decreased when combined with Dosulepin.Approved
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Dosulepin.Approved, Illicit, Investigational
OxymetazolineDosulepin may decrease the antihypertensive activities of Oxymetazoline.Approved
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Dosulepin.Approved, Investigational, Vet Approved
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Dosulepin.Approved, Vet Approved
PaliperidoneDosulepin may decrease the antihypertensive activities of Paliperidone.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Dosulepin.Approved, Investigational
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Dosulepin.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Dosulepin.Approved
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Dosulepin.Approved
PargylinePargyline may increase the serotonergic activities of Dosulepin.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Dosulepin.Approved, Investigational
PazopanibThe metabolism of Pazopanib can be decreased when combined with Dosulepin.Approved
PentamidineThe metabolism of Pentamidine can be decreased when combined with Dosulepin.Approved
PentobarbitalThe metabolism of Dosulepin can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoxifyllineThe serum concentration of Pentoxifylline can be increased when it is combined with Dosulepin.Approved, Investigational
PergolideDosulepin may decrease the antihypertensive activities of Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Dosulepin.Approved, Investigational
PerindoprilThe serum concentration of Dosulepin can be increased when it is combined with Perindopril.Approved
PerospironeThe metabolism of Perospirone can be decreased when combined with Dosulepin.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Dosulepin.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Dosulepin.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Dosulepin.Withdrawn
PhenelzinePhenelzine may increase the serotonergic activities of Dosulepin.Approved
PhenforminThe metabolism of Phenformin can be decreased when combined with Dosulepin.Approved, Investigational, Withdrawn
PhenindioneDosulepin may increase the anticoagulant activities of Phenindione.Approved, Investigational
PheniprazinePheniprazine may increase the serotonergic activities of Dosulepin.Withdrawn
PhenobarbitalThe metabolism of Dosulepin can be increased when combined with Phenobarbital.Approved
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Dosulepin.Withdrawn
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Dosulepin.Approved, Investigational
PhentermineDosulepin may increase the stimulatory activities of Phentermine.Approved, Illicit
PhenylbutazoneThe metabolism of Phenylbutazone can be decreased when combined with Dosulepin.Approved, Vet Approved
PhenylephrineDosulepin may increase the vasopressor activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Dosulepin is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Phenytoin can be decreased when combined with Dosulepin.Approved, Vet Approved
PhosphoramidonThe serum concentration of Dosulepin can be increased when it is combined with Phosphoramidon.Experimental
PimozideThe serum concentration of Pimozide can be increased when it is combined with Dosulepin.Approved
PindololThe metabolism of Pindolol can be decreased when combined with Dosulepin.Approved
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Dosulepin.Approved, Investigational
PiperazineThe metabolism of Piperazine can be decreased when combined with Dosulepin.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Dosulepin.Approved, Investigational
PirbuterolThe risk or severity of adverse effects can be increased when Dosulepin is combined with Pirbuterol.Approved
PirfenidoneThe serum concentration of Pirfenidone can be increased when it is combined with Dosulepin.Approved, Investigational
PirlindolePirlindole may increase the serotonergic activities of Dosulepin.Approved
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Dosulepin.Approved, Investigational
PitavastatinThe metabolism of Pitavastatin can be decreased when combined with Dosulepin.Approved
PivhydrazinePivhydrazine may increase the serotonergic activities of Dosulepin.Withdrawn
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Dosulepin.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Dosulepin.Approved
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Dosulepin.Approved
PravastatinThe metabolism of Pravastatin can be decreased when combined with Dosulepin.Approved
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Dosulepin.Approved, Vet Approved
PrimaquineThe metabolism of Primaquine can be decreased when combined with Dosulepin.Approved
PrimidoneThe metabolism of Dosulepin can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Dosulepin can be increased when it is combined with Prinomastat.Investigational
ProcainamideThe metabolism of Procainamide can be decreased when combined with Dosulepin.Approved
ProcarbazineProcarbazine may increase the serotonergic activities of Dosulepin.Approved
ProcaterolThe risk or severity of adverse effects can be increased when Dosulepin is combined with Procaterol.Approved, Investigational
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Dosulepin.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Dosulepin.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Dosulepin.Approved
PromazineThe metabolism of Promazine can be decreased when combined with Dosulepin.Approved, Vet Approved
PromethazineThe metabolism of Promethazine can be decreased when combined with Dosulepin.Approved
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Dosulepin.Approved
PropofolThe metabolism of Propofol can be decreased when combined with Dosulepin.Approved, Investigational, Vet Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Dosulepin.Approved, Investigational
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Dosulepin.Approved
PseudoephedrineDosulepin may decrease the antihypertensive activities of Pseudoephedrine.Approved
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Dosulepin.Approved
QuazepamThe metabolism of Quazepam can be decreased when combined with Dosulepin.Approved, Illicit
QuetiapineThe metabolism of Quetiapine can be decreased when combined with Dosulepin.Approved
QuinaprilThe serum concentration of Dosulepin can be increased when it is combined with Quinapril.Approved, Investigational
QuinidineDosulepin may increase the QTc-prolonging activities of Quinidine.Approved
QuinineThe metabolism of Quinine can be decreased when combined with Dosulepin.Approved
RacecadotrilThe serum concentration of Dosulepin can be increased when it is combined with Racecadotril.Investigational
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Dosulepin.Approved, Investigational
RamiprilThe serum concentration of Dosulepin can be increased when it is combined with Ramipril.Approved
RanitidineThe metabolism of Ranitidine can be decreased when combined with Dosulepin.Approved
RasagilineThe serum concentration of Rasagiline can be increased when it is combined with Dosulepin.Approved
RemikirenThe serum concentration of Dosulepin can be increased when it is combined with Remikiren.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Dosulepin.Approved, Withdrawn
repinotanThe metabolism of repinotan can be decreased when combined with Dosulepin.Investigational
ResveratrolThe metabolism of Resveratrol can be decreased when combined with Dosulepin.Approved, Experimental, Investigational
RifabutinThe metabolism of Rifabutin can be decreased when combined with Dosulepin.Approved
RifampicinThe metabolism of Rifampicin can be decreased when combined with Dosulepin.Approved
RiluzoleThe metabolism of Riluzole can be decreased when combined with Dosulepin.Approved, Investigational
RisperidoneDosulepin may decrease the antihypertensive activities of Risperidone.Approved, Investigational
RitobegronDosulepin may increase the stimulatory activities of Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Dosulepin is combined with Ritodrine.Approved, Investigational
RitonavirThe metabolism of Ritonavir can be decreased when combined with Dosulepin.Approved, Investigational
RivaroxabanThe serum concentration of Dosulepin can be increased when it is combined with Rivaroxaban.Approved
RizatriptanThe metabolism of Rizatriptan can be decreased when combined with Dosulepin.Approved
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Dosulepin.Investigational, Withdrawn
RopiniroleDosulepin may decrease the antihypertensive activities of Ropinirole.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Dosulepin.Approved
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Dosulepin.Approved, Investigational
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Dosulepin.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Dosulepin.Approved
RucaparibThe metabolism of Rucaparib can be decreased when combined with Dosulepin.Approved, Investigational
RupatadineThe metabolism of Rupatadine can be decreased when combined with Dosulepin.Approved
S-3304The serum concentration of Dosulepin can be increased when it is combined with S-3304.Investigational
SafrazineSafrazine may increase the serotonergic activities of Dosulepin.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Dosulepin is combined with Salbutamol.Approved, Vet Approved
Salicylic acidThe metabolism of Salicylic acid can be decreased when combined with Dosulepin.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Dosulepin is combined with Salmeterol.Approved
SaquinavirThe metabolism of Saquinavir can be decreased when combined with Dosulepin.Approved, Investigational
SaxagliptinThe serum concentration of Dosulepin can be increased when it is combined with Saxagliptin.Approved
SecobarbitalThe metabolism of Dosulepin can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Dosulepin.Approved, Investigational, Vet Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Dosulepin.Approved
SertindoleThe metabolism of Sertindole can be decreased when combined with Dosulepin.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Dosulepin.Approved
SildenafilThe metabolism of Sildenafil can be decreased when combined with Dosulepin.Approved, Investigational
SimeprevirThe serum concentration of Dosulepin can be increased when it is combined with Simeprevir.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Dosulepin.Approved
SitagliptinThe serum concentration of Dosulepin can be increased when it is combined with Sitagliptin.Approved, Investigational
SitaxentanThe metabolism of Sitaxentan can be decreased when combined with Dosulepin.Approved, Investigational, Withdrawn
SivelestatThe serum concentration of Dosulepin can be increased when it is combined with Sivelestat.Investigational
Sodium phosphateThe risk or severity of adverse effects can be increased when Dosulepin is combined with Sodium phosphate.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Dosulepin.Experimental
SpiraprilThe serum concentration of Dosulepin can be increased when it is combined with Spirapril.Approved
St. John's WortThe metabolism of Dosulepin can be increased when combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe metabolism of Stiripentol can be decreased when combined with Dosulepin.Approved
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Dosulepin.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Dosulepin.Approved
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Dosulepin.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Dosulepin.Approved
SulfisoxazoleThe metabolism of Sulfisoxazole can be decreased when combined with Dosulepin.Approved, Vet Approved
SuprofenThe metabolism of Suprofen can be decreased when combined with Dosulepin.Approved, Withdrawn
TacrineThe metabolism of Tacrine can be decreased when combined with Dosulepin.Investigational, Withdrawn
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Dosulepin resulting in a loss in efficacy.Approved
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Dosulepin.Approved, Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Dosulepin.Approved
TasimelteonThe serum concentration of Tasimelteon can be increased when it is combined with Dosulepin.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Dosulepin.Investigational, Withdrawn
TelaprevirThe serum concentration of Dosulepin can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Telithromycin can be decreased when combined with Dosulepin.Approved
TemafloxacinThe metabolism of Temafloxacin can be decreased when combined with Dosulepin.Withdrawn
TemazepamThe metabolism of Temazepam can be decreased when combined with Dosulepin.Approved
TemocaprilThe serum concentration of Dosulepin can be increased when it is combined with Temocapril.Experimental, Investigational
TenoxicamThe metabolism of Tenoxicam can be decreased when combined with Dosulepin.Approved
TerbinafineThe metabolism of Dosulepin can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineThe risk or severity of adverse effects can be increased when Dosulepin is combined with Terbutaline.Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Dosulepin.Withdrawn
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Dosulepin.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Dosulepin.Approved, Investigational
TetrabenazineThe serum concentration of Tetrabenazine can be increased when it is combined with Dosulepin.Approved
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Dosulepin.Approved, Investigational, Withdrawn
TheobromineThe metabolism of Theobromine can be decreased when combined with Dosulepin.Approved, Investigational
TheophyllineThe metabolism of Theophylline can be decreased when combined with Dosulepin.Approved
ThiabendazoleThe metabolism of Thiabendazole can be decreased when combined with Dosulepin.Approved, Vet Approved
ThiamylalThe metabolism of Dosulepin can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Dosulepin can be increased when combined with Thiopental.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Dosulepin.Approved, Withdrawn
ThiorphanThe serum concentration of Dosulepin can be increased when it is combined with Thiorphan.Experimental
ThiothixeneThe metabolism of Thiothixene can be decreased when combined with Dosulepin.Approved
Thyroid, porcineThyroid, porcine may increase the arrhythmogenic activities of Dosulepin.Approved
TiclopidineThe metabolism of Ticlopidine can be decreased when combined with Dosulepin.Approved
TimololThe metabolism of Timolol can be decreased when combined with Dosulepin.Approved
TioclomarolDosulepin may increase the anticoagulant activities of Tioclomarol.Experimental
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Dosulepin.Approved
TipranavirThe metabolism of Tipranavir can be decreased when combined with Dosulepin.Approved, Investigational
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Dosulepin.Approved
TolbutamideThe metabolism of Tolbutamide can be decreased when combined with Dosulepin.Approved
ToloxatoneToloxatone may increase the serotonergic activities of Dosulepin.Approved
TolperisoneThe metabolism of AV650 can be decreased when combined with Dosulepin.Approved, Investigational
TolterodineThe metabolism of Tolterodine can be decreased when combined with Dosulepin.Approved, Investigational
TorasemideThe metabolism of Torasemide can be decreased when combined with Dosulepin.Approved
ToremifeneThe metabolism of Toremifene can be decreased when combined with Dosulepin.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Dosulepin.Approved, Investigational
TramadolDosulepin may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
TrandolaprilThe serum concentration of Dosulepin can be increased when it is combined with Trandolapril.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Dosulepin.Experimental
TranylcypromineTranylcypromine may increase the serotonergic activities of Dosulepin.Approved
TrazodoneThe metabolism of Trazodone can be decreased when combined with Dosulepin.Approved, Investigational
TreprostinilThe metabolism of Treprostinil can be decreased when combined with Dosulepin.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Dosulepin.Approved, Investigational, Nutraceutical
TriamtereneThe metabolism of Triamterene can be decreased when combined with Dosulepin.Approved
TrifluoperazineThe metabolism of Trifluoperazine can be decreased when combined with Dosulepin.Approved
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Dosulepin.Approved
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Dosulepin.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Dosulepin.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Dosulepin.Investigational, Withdrawn
UbenimexThe serum concentration of Dosulepin can be increased when it is combined with Ubenimex.Experimental, Investigational
UlinastatinThe serum concentration of Dosulepin can be increased when it is combined with Ulinastatin.Investigational
UlipristalThe metabolism of Ulipristal can be decreased when combined with Dosulepin.Approved
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Dosulepin.Approved
VadimezanThe metabolism of Vadimezan can be decreased when combined with Dosulepin.Investigational
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Dosulepin.Approved, Investigational
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Dosulepin.Investigational, Withdrawn
Valproic AcidThe serum concentration of Dosulepin can be increased when it is combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Valsartan can be decreased when combined with Dosulepin.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Dosulepin.Approved
VenlafaxineThe serum concentration of Dosulepin can be increased when it is combined with Venlafaxine.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Dosulepin.Approved
VernakalantThe metabolism of Vernakalant can be decreased when combined with Dosulepin.Approved, Investigational
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Dosulepin.Investigational
VilanterolThe risk or severity of adverse effects can be increased when Dosulepin is combined with Vilanterol.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Dosulepin.Approved
VildagliptinThe serum concentration of Dosulepin can be increased when it is combined with Vildagliptin.Approved, Investigational
VinblastineThe metabolism of Vinblastine can be decreased when combined with Dosulepin.Approved
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Dosulepin.Approved, Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Dosulepin.Approved
VoriconazoleThe metabolism of Voriconazole can be decreased when combined with Dosulepin.Approved, Investigational
VortioxetineThe serum concentration of Vortioxetine can be increased when it is combined with Dosulepin.Approved
VoxilaprevirThe metabolism of Voxilaprevir can be decreased when combined with Dosulepin.Approved
WarfarinThe metabolism of Warfarin can be decreased when combined with Dosulepin.Approved
XimelagatranThe metabolism of Ximelagatran can be decreased when combined with Dosulepin.Approved, Investigational, Withdrawn
XylometazolineDosulepin may decrease the antihypertensive activities of Xylometazoline.Approved
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Dosulepin.Approved, Vet Approved
Z-Val-Ala-Asp fluoromethyl ketoneThe serum concentration of Dosulepin can be increased when it is combined with Z-Val-Ala-Asp fluoromethyl ketone.Experimental
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Dosulepin.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Dosulepin.Approved, Investigational
ZaltoprofenThe metabolism of Zaltoprofen can be decreased when combined with Dosulepin.Approved, Investigational
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Dosulepin.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Dosulepin.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Dosulepin can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Ziprasidone can be decreased when combined with Dosulepin.Approved
ZofenoprilThe serum concentration of Dosulepin can be increased when it is combined with Zofenopril.Experimental
ZolmitriptanThe metabolism of Zolmitriptan can be decreased when combined with Dosulepin.Approved, Investigational
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Dosulepin.Approved
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Dosulepin.Approved
ZuclopenthixolThe metabolism of Zuclopenthixol can be decreased when combined with Dosulepin.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Lancaster SG, Gonzalez JP: Dothiepin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs. 1989 Jul;38(1):123-47. [PubMed:2670509]
  2. Maguire KP, Burrows GD, Norman TR, Scoggins BA: Metabolism and pharmacokinetics of dothiepin. Br J Clin Pharmacol. 1981 Sep;12(3):405-9. [PubMed:7295471]
  3. Fulton A, Norman TR, Cheng H, Burrows GD: Assessment of the antidepressant activity of dothiepin and its metabolites by preclinical tests. J Affect Disord. 1982 Sep;4(3):261-9. [PubMed:6215444]
  4. Gillman PK: Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007 Jul;151(6):737-48. Epub 2007 Apr 30. [PubMed:17471183]
  5. Heal D, Cheetham S, Martin K, Browning J, Luscombe G, Buckett R: Comparative pharmacology of dothiepin, its metabolites, and other antidepressant drugs Drug Development Research. 1992 May 1;27(2):121–135.
  6. 45. (2012). In Rang and Dale's Pharmacology (7th ed., pp. 559). Edinburgh: Elsevier/Churchill Livingstone. [ISBN:978-0-7020-3471-8]
  7. Co-pharma Ltd. SUMMARY OF PRODUCT CHARACTERISTICS: Dosulepin hydrochloride tablets [Link]
  8. Alphapharm: DOTHEP (Dothiepin hydrochloride) Product information [Link]
External Links
KEGG Drug
D07872
PubChem Compound
5284550
PubChem Substance
310265076
ChemSpider
4447605
ChEBI
36803
ChEMBL
CHEMBL1492500
Wikipedia
Dosulepin
ATC Codes
N06AA16 — Dosulepin
MSDS
Download (599 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)131- 134.6MSDS
boiling point (°C)339.8- 341.6MSDS
water solubilityPartly miscibleMSDS
Predicted Properties
PropertyValueSource
Water Solubility0.000572 mg/mLALOGPS
logP4.98ALOGPS
logP4.52ChemAxon
logS-5.7ALOGPS
pKa (Strongest Basic)9.76ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area3.24 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity104.59 m3·mol-1ChemAxon
Polarizability34.57 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dibenzothiepins. These are compounds containing a dibenzothiepin moiety, which consists of two benzene connected by a thiepine ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzothiepins
Sub Class
Dibenzothiepins
Direct Parent
Dibenzothiepins
Alternative Parents
Alkylarylthioethers / Benzenoids / Trialkylamines / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Dibenzothiepin / Aryl thioether / Alkylarylthioether / Benzenoid / Tertiary aliphatic amine / Tertiary amine / Thioether / Organic nitrogen compound / Organopnictogen compound / Hydrocarbon derivative
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
dothiepin (CHEBI:36803)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da
References
  1. Fulton A, Norman TR, Cheng H, Burrows GD: Assessment of the antidepressant activity of dothiepin and its metabolites by preclinical tests. J Affect Disord. 1982 Sep;4(3):261-9. [PubMed:6215444]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Fulton A, Norman TR, Cheng H, Burrows GD: Assessment of the antidepressant activity of dothiepin and its metabolites by preclinical tests. J Affect Disord. 1982 Sep;4(3):261-9. [PubMed:6215444]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Gillman PK: Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007 Jul;151(6):737-48. Epub 2007 Apr 30. [PubMed:17471183]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Gillman PK: Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007 Jul;151(6):737-48. Epub 2007 Apr 30. [PubMed:17471183]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
G-protein coupled acetylcholine receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM2
Uniprot ID
P08172
Uniprot Name
Muscarinic acetylcholine receptor M2
Molecular Weight
51714.605 Da
References
  1. Gillman PK: Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007 Jul;151(6):737-48. Epub 2007 Apr 30. [PubMed:17471183]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM3
Uniprot ID
P20309
Uniprot Name
Muscarinic acetylcholine receptor M3
Molecular Weight
66127.445 Da
References
  1. Gillman PK: Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007 Jul;151(6):737-48. Epub 2007 Apr 30. [PubMed:17471183]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Guanyl-nucleotide exchange factor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM4
Uniprot ID
P08173
Uniprot Name
Muscarinic acetylcholine receptor M4
Molecular Weight
53048.65 Da
References
  1. Gillman PK: Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007 Jul;151(6):737-48. Epub 2007 Apr 30. [PubMed:17471183]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM5
Uniprot ID
P08912
Uniprot Name
Muscarinic acetylcholine receptor M5
Molecular Weight
60073.205 Da
References
  1. Gillman PK: Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007 Jul;151(6):737-48. Epub 2007 Apr 30. [PubMed:17471183]
Kind
Protein group
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...

Components:
References
  1. Heal D, Cheetham S, Martin K, Browning J, Luscombe G, Buckett R: Comparative pharmacology of dothiepin, its metabolites, and other antidepressant drugs Drug Development Research. 1992 May 1;27(2):121–135.
Kind
Protein group
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...

Components:
References
  1. Heal D, Cheetham S, Martin K, Browning J, Luscombe G, Buckett R: Comparative pharmacology of dothiepin, its metabolites, and other antidepressant drugs Drug Development Research. 1992 May 1;27(2):121–135.
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Norepinephrine:sodium symporter activity
Specific Function
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A2
Uniprot ID
P23975
Uniprot Name
Sodium-dependent noradrenaline transporter
Molecular Weight
69331.42 Da
References
  1. Gillman PK: Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007 Jul;151(6):737-48. Epub 2007 Apr 30. [PubMed:17471183]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serotonin:sodium symporter activity
Specific Function
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
Gene Name
SLC6A4
Uniprot ID
P31645
Uniprot Name
Sodium-dependent serotonin transporter
Molecular Weight
70324.165 Da
References
  1. Gillman PK: Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007 Jul;151(6):737-48. Epub 2007 Apr 30. [PubMed:17471183]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Gillman PK: Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007 Jul;151(6):737-48. Epub 2007 Apr 30. [PubMed:17471183]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Gillman PK: Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007 Jul;151(6):737-48. Epub 2007 Apr 30. [PubMed:17471183]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Gillman PK: Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007 Jul;151(6):737-48. Epub 2007 Apr 30. [PubMed:17471183]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Gillman PK: Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007 Jul;151(6):737-48. Epub 2007 Apr 30. [PubMed:17471183]

Drug created on October 13, 2015 17:52 / Updated on December 01, 2017 17:27